Lilly's Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
May 4, 2026 9:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Buy rating and $1,283.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Shares of LLY are down ~2% in early trading following a post in the FDA Adverse event monitoring system of a patient... More
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
May 4, 2026 8:58 AM EDTBarclays analyst Emily Field raised the price target on Eli Lilly (NYSE: LLY) to $1,400.00 (from $1,350.00) while maintaining a Overweight rating.
The analyst comments "A remarkably strong quarter...and LLY's only just getting started. Reiterate OW rating and raise PT to $1,400: We update our model following LLY's 1Q26 report (see Eli Lilly & Co: 1Q26 First Take: Mounjaro ex-US (+ a bit of US price) drive DD% top and bottom line beat & raise...call to focus on Foundayo (04/30/26)...where... More
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
May 4, 2026 8:57 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $1,325.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "FAERS reports hepatic safety signal for Foundayo. On April 30th, the FDA received data via its FDA Adverse Event Reporting System (FAERS) suggesting that a patient dosed with Lilly (LLY)'s Foundayo, an oral small-molecule GLP-1, reported a case of serious hepatic failure. Given the importance of Foundayo's safety profile in unlocking the broader PCP prescribing opportunity, we reached out to LLY for further color behind the signal. Here, the company largely... More
